Frankfurt
24.01.25
15:29 Uhr
3,220 Euro
+0,100
+3,21 %
+3,21 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| Di | Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study | 1 | Zacks | ||
| Di | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| Di | Nanobiotix S.A.: NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer | 102 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based... ► Artikel lesen | |
| 10.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.01. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 17.12.24 | Nanobiotix S.A.: NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 | 2 | GlobeNewswire (USA) | ||
| 17.12.24 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.12.24 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 09.12.24 | Nanobiotix S.A.: NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer | 223 | GlobeNewswire (Europe) | Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date... ► Artikel lesen | |
| 09.12.24 | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.11.24 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 4 | GlobeNewswire (USA) | ||
| 12.11.24 | Nanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms | 197 | GlobeNewswire (Europe) | Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory... ► Artikel lesen | |
| 11.10.24 | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 5 | GlobeNewswire (USA) | ||
| 11.10.24 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 18.09.24 | Nanobiotix reports 1H results | 2 | Seeking Alpha | ||
| 18.09.24 | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results | 271 | GlobeNewswire (Europe) | RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune... ► Artikel lesen | |
| 18.09.24 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 04.09.24 | Nanobiotix S.A.: NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth | 3 | GlobeNewswire (USA) | ||
| 03.09.24 | Nanobiotix S.A.: Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 03.09.24 | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | 0,079 | -100,00 % | Prusa gibt Update zum 3D-Drucker CORE One: Erste Auslieferungen stehen bevor | ||
| PALATIN TECHNOLOGIES | 0,923 | +0,65 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,900 | +5,07 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| AMYRIS | - | - | BioMaP-Consortium Contracts Amyris to Support Domestic Medicines Supply | ||
| HALOZYME THERAPEUTICS | 53,24 | -0,34 % | Halozyme nach geplatzter Evotec-Übernahme: Prognose rauf! | Mitte November sorgte das US-amerikanische Biotech-Unternehmen Halozyme Therapeutics in Deutschland für Schlagzeilen. Die Firma wollte sich den deutschen Wirkstoffforscher Evotec einverleiben, der den... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,360 | -0,41 % | Abcellera Biologics, other AI health stocks gain as Ellison touts AI's promise | ||
| GLOW LIFETECH | 0,035 | +1,45 % | Glow LifeTech Corp.: Glow Lifetech Announces Expansion into New Brunswick Market with MOD Drops, Marking Atlantic Canada Debut | Toronto, Ontario--(Newsfile Corp. - January 13, 2025) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its expansion of its flagship MOD drops... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 334,90 | -1,30 % | Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now | ||
| AVID BIOSERVICES | 11,900 | 0,00 % | Avid Bioservices, Inc: Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand | TUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| BIOLINERX | 0,109 | -0,91 % | BioLineRx Ltd.: BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares | TEL AVIV, Israel, Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing... ► Artikel lesen | |
| AADI BIOSCIENCE | 2,760 | -4,83 % | Aadi Bioscience +72%: NBC-Kursrakete startet über Nacht | Riesengeschenk kurz vor Weihnachten: Mitglieder des exklusiven Anlegerclubs No Brainer Club (NBC) und Teilnehmer eines Webinars feiern am Freitag eine sensationelle Kursrakete. Die Aktie von Aadi Bioscience... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,040 | -0,97 % | Minerva Neurosciences Stock Hits 52-Week Low at $2.03 | ||
| APPLIED THERAPEUTICS | 0,615 | +3,80 % | Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality | ||
| GEOVAX LABS | 2,685 | 0,00 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| COCRYSTAL | 1,960 | +3,70 % | Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 | Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged... ► Artikel lesen |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,21 % bei einem Aktienkurs von 3,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.
